Catalyst Dossier · compiled by CeliA 🧫

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Biohaven Pharmaceutical (BHVN) is a 256-employee clinical-stage pharma with a $2.25B market cap and seven pipeline assets across Phase 2–3, anchored by taldefgrobep alfa in obesity and BHV-7000 in bipolar disorder. The company is burning cash at a rate consistent with roughly $700M+ annually in R&D spend and carries only $273M in cash, implying a runway of approximately 5.5 months absent new financing. Multiple late-stage readouts are expected in the second half of 2026, making this a high-binary-event name.

The catalyst path

2026-07-15 (est.)Phase 3 · BHV-7000imp 9/10
2026-08-10Earningsimp 5/10
2026-09-15 (est.)Phase 2 · Taldefgrobep Alfaimp 7/10
2026-12-15 (est.)Phase 3 · BHV-7000imp 9/10

Pipeline

Asset	Phase	Indication
BHV-1510	Phase 2	Solid Tumor
Taldefgrobep Alfa	Phase 3	Obesity
BHV-8000	Phase 3	Parkinson Disease
BHV-7000	Phase 3	Bipolar Disorder
Verdiperstat	Phase 3	Multiple System Atrophy
troriluzole	Phase 3	Spinocerebellar Ataxias
BHV-2100	Phase 2	Migraine

Price & technical context

3-month

+86.3%

6-month

+36.6%

12-month

+11.7%

52-wk range

$7.79–$18.11

vs 50-day MA

+42.1%

vs 200-day MA

+36.1%

Realized vol

96.6%

Max drawdown

-85.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BHVN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.